Respiratory Virus Metagenomics After COVID-19
Launched by CHINESE UNIVERSITY OF HONG KONG · Nov 17, 2021
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
The clinical trial titled "Respiratory Virus Metagenomics After COVID-19" is studying how different viruses, especially after a COVID-19 infection, are present in the upper respiratory tract. Researchers want to understand how these viruses are linked to flu seasons, the symptoms people experience, and where they might have been exposed to these viruses. The trial will involve 500 adults living in Hong Kong who will fill out a questionnaire and provide nasal and throat swabs for testing.
To participate in this study, you need to be an adult who lives in Hong Kong, can communicate in English or Chinese, and is willing to give your consent. Unfortunately, individuals with mental health issues or those who are currently imprisoned cannot take part. If you join, you can expect to help researchers learn more about respiratory viruses, which could benefit public health in the future. Your contribution may help improve our understanding of how respiratory infections behave, especially after COVID-19.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adults normally residing in Hong Kong
- • could communicate in English and/or Chinese
- • provision of consent
- Exclusion Criteria:
- • individuals with mental illness
- • prisoners
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, Hong Kong, China
Patients applied
Trial Officials
Shui Shan Lee
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials